Cyclooxygenase-2 expression in primary and recurrent pterygium

European Journal of Ophthalmology

Volumn 17, Issue 6, 2007, Pages 879-884

  Adigüzel, Ufuk ^a   Karabacak, T ^a   Sari, A ^a   Oz, O ^a   Cinel, L ^a  

^a MERSIN UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Cyclooxygenase 2; Primary; Pterygium; Recurrent

Indexed keywords

CYCLOOXYGENASE 2; ENZYME ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONJUNCTIVA TUMOR; CONTROLLED STUDY; CYTOPLASM; EPITHELIUM CELL; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEMBRANE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTERYGIUM; RECURRENT DISEASE; STAINING; STATISTICAL SIGNIFICANCE;

EID: 39349087595     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.1177/112067210701700602     Document Type: Article

References (37)

1. Clear AS, Chirambo MC, Hutt MSR. Solar keratosis, pterygium, and squamous cell carcinoma of the conjunctiva in Malawi. Br J Ophthalmol 1979; 63: 102-9.
2. Frucht-Pery J, Siganos CS, Islar M. Intraoperative application of topical mitomycin C for pterygium surgery. Ophthalmology 1996; 103: 674-7.
3. Lam DS, Wong AK, Fan DS, Chew S, Kwok PS, Tso MO. Intraoperative mitomycin C to prevent recurrence of pterygium after excision: a 30-month follow-up study. Ophthalmology 1998; 105: 901-4.
4. Sanchez-Thorin JC, Rocha G, Yelin JB. Meta-analysis on the recurrence rates after bare sclera resection with and without mitomycin C use and conjunctival autograft placement in surgery for primary pterygium. Br J Ophthalmol 1998; 82: 661-5.
5. Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol 1984; 68: 343-6.
6. Taylor HR. Ultraviolet radiation and the eye: an epidemiologic study. Trans Am Ophthalmol Soc 1989; 87: 802-53.
7. Girolamo ND, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Progr Retin Eye Res 2004; 23: 195-228.
8. Chiang CC, Cheng YW, Lin CL, et al. Cyclooxygenase 2 expression in pterygium. Mol Vis 2007; 13: 635-8.
9. Dempke W, Rie C, Grothey A, Schmoll HJ. Cyclooxygenase-2: a novel target for cancer chemotherapy? J Cancer Res Clin Oncol 2000; 127: 411-7.
10. Fosslien E. Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 2000; 30: 3-21.
11. Zoumpourlis V, Solakidi S, Papathoma A, Papaevangeliou D. Alterations in signal transduction pathways implicated in tumour progression during multistage mouse skin carcinogenesis. Carcinogenesis 2003; 24: 1159-65.
12. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003; 7: 207-22.
13. Tan DT, Chee SP, Dear KB, Lim AS. Effect of pterygium morphology on pterygium recurrence in a controlled trial comparing conjunctival autografting with bare sclera excision. Arch Ophthalmol 1997; 115: 1235-40.
14. Putti TC, Teh M, Lee YS. Biological behavior of keratoacanthoma and squamous cell carcinoma: telomerase activity and COX-2 as potential markers. Mod Pathol 2004; 17: 468-75.
15. Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996; 35: 711-8.
16. Siegle I, Klein T, Backman JT, Saal JG, Nusing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998; 41: 122-9.
17. Tomasoni S, Noris M, Zappella S, et al. Upregulation of renal and systemic cyclooxygenase-2 in patients with active lupus nephritis. J Am Soc Nephrol 1998; 9: 1202-12.
18. Konuk EB, Konuk O, Misirlioglu M, Menevse A, Unal M. Expression of cyclooxygenase-2 in orbital fibroadipose connective tissues of Graves' ophthalmopathy patients. Eur J Endocrinol 2006; 155: 681-5.
19. Oka T, Shearer T, Azuma M. Involvement of cyclooxygenase-2 in rat models of conjunctivitis. Curr Eye Res 2004; 29: 27-34.
20. Biswas PS, Banerjee K, Kim B, Kinchington PR, Rouse BT. Role of inflammatory cytokine induced cyclooxygenase 2 in the ocular immunopathologic disease herpetic stromal keratitis. J Virol 2005; 16: 10589-600.
21. Sellers RS, Silverman L, Khan KN. Cyclooxygenase-2 expression in the cornea of dogs with keratitis. Vet Pathol 2004; 41: 116-21.
22. Miyamoto T, Saika S, Okada Y, et al. Expression of cyclooxygenase-2 in corneal cells after photorefractive keratectomy and laser in situ keratomileusis in rabbits. J Cataract Refract Surg 2004; 30: 2612-7.
23. Amico C, Yakimov M, Catania MV, Giuffrida R, Pistone M, Enea V. Differential expression of cyclooxygenase-1 and cyclooxygenase-2 in the cornea during wound healing. Tissue Cell 2004; 36: 1-12.
24. Miyamoto T, Saika S, Ueyama T, et al. Cyclooxygenase 2 expression in rat corneas after ethanol exposure. J Cataract Refract Surg 2006; 32: 1736-40.
25. Yamada M, Kawai M, Kawai Y, Mashima Y. The effect of selective cyclooxygenase-2 inhibitor on corneal angiogenesis in the rat. Curr Eye Res 1999; 19: 300-4.
26. Kuwano T, Nakao S, Yamamoto H, et al. Cyclooxygenase 2 is a key enzyme for inflammatory cytokine-induced angiogenesis. Faseb J 2004; 18: 300-10.
27. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UV-B exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-9.
28. Iniguez MA, Rodriguez A, Volpert OV, Fresno M, Redondo JM. Cyclooxygenase-2: a therapeutic target in angiogenesis. Trends Molec Med 2003; 9: 73-8.
29. Chen W, Tang Q, Gonzales MS, Bowden GT. Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene 2001; 20: 3921-6.
30. An KP, Athar M, Tang X, et al. Cyclooxygenase-2 expression in murine and human nonmelanoma skin cancers: implications for therapeutic approaches. Photochem Photobiol 2002; 76: 73-80.
31. Athar M, An KP, Morel KD, et al. Ultraviolet B (UVB)-induced cox-2 expression in murine skin: an immunohistochemical study. Biochem Biophys Res Commun 2001; 280: 1042-7.
32. Fischer SM, Lo HH, Gordon GB, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog 1999; 25: 231-40.
33. Fischer SM, Conti CJ, Viner J, Aldaz CM, Lubet RA. Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice. Carcinogenesis 2003; 24: 945-52.
34. Pentland AP, Schoggins JW, Scott GA, Khan KN, Han R. Reduction of UV-induced skin tumors in hairless mice by selective COX-2 inhibition. Carcinogenesis 1999; 20: 1939-44.
35. Orengo IF, Gerguis J, Phillips R, Guevara A, Lewis AT, Black HS. Celecoxib, a cyclooxygenase 2 inhibitor as a potential chemopreventive to UV-induced skin cancer: a study in the hairless mouse model. Arch Dermatol 2002; 138: 751-5.
36. Wilgus TA, Koki AT, Zweifel BS, Kusewitt DF, Rubal PA, Oberyszyn TM. Inhibition of cutaneous ultraviolet light B-mediated inflammation and tumor formation with topical celecoxib treatment. Mol Carcinog 2003; 38: 49-58.
37. Wilgus TA, Breza TS, Tober KL, Oberyszyn TM. Treatment with 5-fluorouracil and celecoxib displays synergistic regression of ultraviolet light B-induced skin tumors. J Invest Dermatol 2004; 122: 1488-94.